Oregon Health and Science University

Collaborative Cancer Cloud expands to drive medicines to patients faster

Monday, April 11, 2016

The Dana-Farber Cancer Institute (DFCI) of Boston and the Ontario Institute for Cancer Research (OICR) in Toronto have joined the Collaborative Cancer Cloud, a partnership formed in August 2015 by the Knight Cancer Institute at Oregon Health and Science University (OHSU) of Portland, Oregon, and Intel. By allowing research institutions to securely share genomic, imaging and clinical data on a precision medical analytics platform, the Collaborative Cancer Cloud is positioning itself to make rapid strides in cancer research and lifesaving therapies.

[Read More]

Dana-Farber, Ontario Institute join collaborative cancer cloud

Friday, April 1, 2016

The Knight Cancer Institute at Oregon Health & Science University and Intel are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario Institute for Cancer Research. The institutions will join the OHSU Knight Cancer Institute in leveraging Intel’s technology to securely share and analyze their collectively large amounts of data, while preserving the privacy and security of patient data at each site.

[Read More]

NIH Council of Councils members named

Monday, June 22, 2015

The National Institutes of Health has announced the appointment of eight individuals to the NIH Council of Councils. The council was established to advise the NIH director on policies and activities of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), including making recommendations on research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis or would otherwise benefit from strategic planning and coordination.

[Read More]

West Nile virus vaccine now in phase I clinical trials

Thursday, May 14, 2015

A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored phase I, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use.

[Read More]

NIH awards $64M for the understanding of cell pathways, development of new therapies

Tuesday, September 16, 2014

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

[Read More]